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Abstract
Purpose: Despite the benefits of estrogen receptor (ER)-targeted endocrine therapies in breast cancer, many tumors
develop resistance. MicroRNAs (miRNAs) have been suggested as promising biomarkers and we here evaluated whether a
miRNA profile could be identified, sub-grouping ER+ breast cancer patients treated with adjuvant Tamoxifen with regards to
probability of recurrence.
Experimental Design: Global miRNA analysis was performed on 152 ER+ primary tumors from high-risk breast cancer
patients with an initial discovery set of 52 patients, followed by two independent test sets (N=60 and N=40). All patients
had received adjuvant Tamoxifen as mono-therapy (median clinical follow-up: 4.6 years) and half had developed distant
recurrence (median time-to-recurrence: 3.5 years). MiRNA expression was examined by unsupervised hierarchical clustering
and supervised analysis, including clinical parameters as co-variables.
Results: The discovery set identified 10 highly significant miRNAs that discriminated between the patient samples according
to outcome. However, the subsequent two independent test sets did not confirm the predictive potential of these miRNAs.
A significant correlation was identified between miR-7 and the tumor grade. Investigation of the microRNAs with the most
variable expression between patients in different runs yielded a list of 31 microRNAs, eight of which are associated with
stem cell characteristics.
Conclusions: Based on the large sample size, our data strongly suggests that there is no single miRNA profile predictive of
outcome following adjuvant Tamoxifen treatment in a broad cohort of ER+ breast cancer patients. We identified a sub-
group of Tamoxifen-treated breast cancer patients with miRNA-expressing tumors associated with cancer stem cell
characteristics.
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Introduction
Approximately 85% of breast carcinomas are estrogen receptor
(alpha) positive (ER+), rendering these patients eligible for
endocrine treatment with aromatase inhibitors (AIs) or Tamoxifen
[1]. Adjuvant treatment with Tamoxifen significantly reduces the
risk of recurrence and death in all age groups of ER+ patients. A
meta-analysis of 21,457 women with breast cancer included in
20 trials of adjuvant Tamoxifen therapy showed a reduction of 15-
year breast cancer mortality rates by at least a third [2].
Although Tamoxifen is of great benefit for many patients,
recurrence occurs in approximately 30% after 15-years of
follow-up [2]. Consequently, ongoing development of drugs for
ER+ breast cancer has led to the development of third
generation AIs, such as the non-steroidal agents Anastrazol
and Letrozol and the steroidal agent Exemestane, which have
increased efficacy compared to Tamoxifen in post-menopausal
women [3–5]. Despite overall superiority of the AIs, Tamoxifen
is still the recommended treatment modality for pre-menopausal
breast cancer patients and patients resistant to AIs. In addition,
the side-effect profile of the drugs differs, and some patients
may not be candidates for treatment with a given drug due to
co-morbidities. It is, therefore, rational to maintain Tamoxifen
as an adjuvant treatment option, but the AIs have increased the
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36170need for more precise stratification of patients to ensure optimal
patient care and the best use of health care budgets.
Micro-RNAs (miRNAs) are a class of non-coding, short RNAs
(an average of 22 nucleotides) that function as post-transcriptional
regulators by targeting mRNAs and causing either inhibition of
translation or degradation of mRNA [6]. In essence, miRNAs add
an extra level of regulation to gene expression, and studies are
rapidly emerging on their role in diseases, including cancer. Their
involvement in cancer is supported by an early finding that .50%
of the miRNAs reside in cancer-associated chromosomal regions,
e.g. regions of loss-of-heterozygocity, or common fragile sites [7].
Various studies have identified miRNAs that may be involved in
ER regulation, and this mechanism has been proposed to be
involved in the varying clinical benefits of Tamoxifen. MiR-206
was the first miRNA reported to be in a feedback loop with ERa
[8]. To date, around 15 miRNAs have been identified that
regulate the protein expression of ERa either directly or indirectly
through interacting proteins, whereas the expression of three
miRNAs (miR-206, miR-21 and miR-17,92) has been found to
be regulated by ERa/-b [9]. All of these studies were done using
cell lines. The first report investigating Tamoxifen was on the
hepato-carcinogenic effect of Tamoxifen in rats, finding an up-
regulation of miR-17,92, miR-206a and miR-34 in the liver after
long-term exposure (24 weeks) to Tamoxifen [10].
Only a few studies have directly examined the role of miRNAs
in Tamoxifen resistance, the vast majority of which were
conducted using cell lines. These studies have yielded a list of
miRNAs that may potentially be involved in resistance; miR-128a
[11], miR-181, miR-489, miR-21 and miR-342 [12], miR-15a,
miR-16 [13] and miR-101 [14].
Studies investigating patient material have been small and used
clinical tumor material different that that used in the present study
(primary tumors from patients who received Tamoxifen mono-
therapy in the adjuvant setting). In one study, the miR-221/-222
cluster was found in cell lines to negatively regulate the ERa and
was subsequently identified in 4/16 ER+ patients vs. 13/25 ER-
patients. In addition, miR-221/-222 has been found to have
higher expression in HER2-positive tumor samples, which are
associated with poor outcome in Tamoxifen-treated patients (the
ER status was not provided) [12].
In another study, miR-30c was identified as an independent
predictor of Tamoxifen efficacy in advanced breast cancer
patients. This patient population had already developed metastasis
prior to the onset of treatment and the benefit of treatment was
measured as an objective response according to the REMARK
criteria [15]. Another recent study showed that miR-210 was
associated with outcome in 56 untreated breast cancer patients,
thereby providing a marker of breast cancer aggressiveness. This
miRNA was confirmed to predict outcome in a treated population
of 89 Tamoxifen-treated ER+ breast cancer patients [16]. Finally,
a small study examining 15 post-menopausal, ER+ breast cancer
patients receiving Exemestane (an AI) and Tamoxifen for 4
months prior to surgery found up-regulation of a panel of miRNAs
after treatment (miR-21, miR181b, miR-26a/26b, miR-27b and
miR-23b), providing insight into the effect of Exemestane and
Tamoxifen on miRNA expression [17]. However, this study did
not report a possible association between pre-treatment miRNAs
and benefit of treatment, likely due to the small sample size.
The intent of our study was to obtain biological information on
miRNA expression in a large cohort of ER+ breast cancer patients
enrolled in the endocrine DBCG-89c/-99c trials, in which patients
had been treated with adjuvant Tamoxifen, and to examine
whether miRNAs could sub-stratify this patient population with
regard to outcome. LNA-enhanced microarrays were used to
measure global miRNA expression in primary ER+ tumors from
high-risk, post-menopausal, breast cancer patients.
Methods
Patient Material
All included patients underwent primary breast cancer surgery
at Odense University Hospital and were enrolled in the endocrine
protocols of the Danish Breast Cancer Co-operative Group
(DBCG) 89c or 99c [18]. All patients had archival formalin-fixed,
paraffin-embedded, (FFPE) tumor tissue stored in the dark at room
temperature. Clinical information was obtained from the DBCG.
Inclusion criteria: ER+ tumor, post-menopausal, mono-systemi-
cally treated with Tamoxifen for .3 months and diagnosed at
least 5 years prior to initiation of the study. Furthermore, the
tumor was only included if the content of tumor cells was .50, as
assessed by haematoxylin and eosin (HE)-stained sections.
Exclusion criteria: bilateral breast cancer, recurrence ,3 months
of diagnosis, treatment with adjuvant chemotherapy/AIs, second-
ary cancers (except for cancer cutis) and/or unavailable medical
records. Follow-up, or disease-free survival (DFS), was defined as
time between diagnosis and date of last flow sheet for patients
without recurrence (denoted N), or date of recurrence (denoted R).
Overall survival (OS) was defined as period from date of surgery to
nationally registered death from any cause. The study was initiated
with a discovery set consisting of 26/26 samples from patients
experiencing recurrence/no recurrence, respectively, followed by
two independent test sets of 30/30 and 19/21 samples,
respectively, from patients experiencing recurrence/no recur-
rence. The clinical characteristics are listed in Table 1. A power
calculation was made to determine the number of samples needed
to assure a statistically significant conclusion could be drawn. The
power calculation was based on the following parameters: desired
power 0.80, 2-fold expected difference, per-gene alpha 0.002,
standard deviation estimate 0.7. The minimum number of patient
samples per group/set was determined to be 16, and no further
gain was likely at 30 or more patients per group/set. [20]
Biological distribution between the recurrent vs. non-recurrent
groups for each of the 3 sets was investigated by a 2-sided Students
t-test. The study was approved by the Ethical Committee of Funen
and Vejle County (VF20040064), The Danish Data Protection
Agency (2004-53-0950) and the Danish Breast Cancer Coopera-
tive Group (DBCG). The study was retrospective and we did not
obtain informed consent from the participants involved in the
study as approved by the Ethical Committee.
RNA Isolation, Labeling, Hybridization, and Scanning
Five sections of 10 mm were de-paraffinized and total RNA was
extracted with Roche high pure kit according to the manufactur-
er’s protocol (Roche, Basel, Switzerland). RNA quality and
quantity was determined by NanoDrop spectrophotometer
(Thermo Scientific, Wilmington, DE, USA). A common reference
design wherein the common reference contained an equimolar
mixture of total RNA from all samples per set was applied to allow
both one and two-channel analysis of the data. The sample
channel was labeled with Hy3
TM dye, while the reference channel
was labeled with Hy5
TM dye according to the manufacturer’s
recommendation (Exiqon A/S, Vedbaek, Denmark). Labeled
RNA was hybridized overnight to miRCURY LNA
TM microRNA
arrays (see GSE37405 for details on the array features) on a Tecan
HS Pro 4800 hybridization station. The arrays contained .3300
different Tm normalized capture probes, all in tetraplicates,
against all human and viral microRNAs annotated in miRBase 15,
as well as a number of proprietary microRNAs not yet included in
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bridization, the rinsed and dried arrays were scanned in a DNA
microarray scanner (Agilent, model G2565BA, California, USA).
Data Processing and Statistical Analysis
The data was treated as one channel data using the Hy3 signal
intensities, and as two-channel data using the Hy3/Hy5 ratios. We
present only the one-channel data since the ratio analysis gave
comparable results. Initially, background subtraction was per-
formed in R v.2.2.1 using the backgroundCorrectmethod in the
LIMMA (Linear Models for Microarary Data) package, which is
available as part of the Bioconductor project (http://www.
bioconductor.org). The intensity values were then log2-scaled
and the median probe signals were quantile normalized. Thus, the
statistical analysis is based on the quantile normalized log2-scaled
Hy3 signals.
The discovery set was used to examine the differences between
the N and R samples, and between other clinical variables
(according to Table 1), using a Student’s T-test. Data were
visualized by dynamic PCA (principal component analysis) and in
heat-maps with two-way unsupervised hierarchical clustering using
Qlucore Omics Explorer v.2.2 (Qlucore AB, Lund, Sweden). For
DFS and OS analysis, Kaplan-Meier plots and the Cox
proportional-hazards regression model were applied to all three
sets, using the R package ‘‘survival’’, investigating the 10 miRNAs
identified in the discovery set. A step-forward ANOVA model
(used to limit type 1 errors when comparing more than one mean)
was used for pair-wise comparison of microRNA biomarkers to
clinical characteristics (e.g. grade). Subsequently, the two inde-
pendent test sets were analyzed separately using supervised
clustering for N vs. R samples to examine whether the identified
miRNAs overlapped between the 3 sets.
An unsupervised analysis to identify potentially important
miRNAs not associated with known clinical parameters was
conducted. For each of the 3 data sets, the standard deviation was
calculated and the 100 most variable miRNAs, per set, was
compared with the other sets, identifying miRNAs that overlapped
in all 3 sets. The biological association of the identified miRNAs
were investigated using the miR2Disease database (www.
mir2disease.org) [19]. This is shown in Table S1, which also
includes experimentally verified targets.
Results
Patients
All patients had received adjuvant Tamoxifen as mono-therapy
and enrolled in the DBCG cohorts 89c or 99c [18,20]. Initially, a
database retrieval of patients enrolled in the aforementioned
endocrine protocols at Odense University Hospital was conducted
by the DBCG. Eligible patients fulfilling the inclusion/exclusion
criteria were grouped according to recurrence status. In total,
there were 246 patients without recurrence and 80 with
recurrence. The former patients were consistently the limiting
factor. The median clinical follow-up was 4.6 years (range 0.7–
14.9 years), and the most recently diagnosed patient was from
2001. Patient and tumor characteristics are provided in Table 1.
Table 1. Characteristics of included patients and their breast cancer tumor (N=152).
RDisc. NDisc. RTest#1 NTest#2 RTest#2 NTest#2
(n=26) (n=26) (n=30) (n=30) (n=19) (n=21)
Age 59.2 62.8 61.5 62.7 59.1 60
Avg. (range), years (48–73) (49–74) (49–70) (52–72) (50–72) (49–72)
Size 33.19 30.1 31.4 26.2 28.4 20.5
Avg. (range), mm (12–85) (14–95) (7–80) (8–58) (8–65) (10–45)
Positive lymph node 4.7 4.5 8.6 3.0 3.3 1.6
Avg (range) (0–13) (0–13) (1–29) (0–14) (0–11) (0–8)
ER status (avg. %/median %)
a 91.4/95 85.9/100 77.9/90 83.9/83 82.4/92.5 83.1/90
Positive
b 417 1 2 6 5
Negative 1 0 1 3 0 0
Unknown 0 2 1 3 1 0
PgR status (avg. %/median %)
a 73.2/80 81.3/90 65/72.5 70.2/80 32.9/15 36.8/10
Positive
b 319 91 0
Negative 6 7 11 5 2 6
Unknown 0 2 2 1 5 6
Diagnosis (IDC/ILC/unknown) 20/6/0 20/6/0 25/4/1 26/3/1 15/1/3 18/0/3
Tamoxifen 1.8 2.1 1.7 1.6 3.1 4.5
Avg (range), years (0.3–5.0) (0.7–5.0) (0.8–5.2) (0.8–5.3) (1.7–5.0) (2.7–5.0)
TTR 3.4 – 3.7 – 3.6 –
Avg (range), years (0.7–8.7) (0.8–14.9) (0.8–8.7)
athe average and median were calculated only for the tumors defined as positive, i.e. staining was observed in $ 10% of tumor cells by immunohistochemistry.
bIf the actual percentage was not provided, patients were deemed positive if ER staining was observed in $ 10% of tumor cells by immunohistochemistry and/or target
protein (ER or PgR) was .10 fmol/mg total protein as determined by biochemistry.
cthe 5 ER- tumors had a PgR status of 90%, 50%, 90%, 80% and IHC+ (i.e. .10%) respectively.
Abbreviations: R: patients with recurrence. N: patients without recurrence. Disc.: Discovery set. Test#1: Test set#1. Test#2: Test set#2. Avg: average IDC: invasive ductal
carcinoma. ILC: invasive lobular carcinoma. TTR: time to recurrence.
doi:10.1371/journal.pone.0036170.t001
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divided according to recurrence status (Table 1), to accentuate
underlying biological differences. The two patient groups (recur-
rence/no recurrence) were paired according to strong prognostic
factors influencing the probability of recurrence, including number
of positive lymph nodes and size of the tumor as well as duration of
Tamoxifen treatment. Age was not a criterion for matching as all
patients were post-menopausal. Matching was conducted to the
precise number of tumor-infiltrated lymph nodes, which restricted
the number of eligible patient-pairs.
Two independent test sets were used to examine the findings of
the discovery set and included the remainder of the 89c/99c
enrolled patients randomly selected from the previously-men-
tioned DBCG database retrieval. The only criterion was that half
of the patients should have recurrence while the other half should
not (Table 1), leading to a distribution resembling the complete
nationwide 89c cohort as observed by the histological subtype.
The 89c cohort is representative of this study in that it enrolled
high-risk, ER+, post-menopausal breast cancer patients, and
approximately 75% of the studied patients were part of 89c [20].
Microarray Analysis
Global miRNA analysis of the 152 primary breast cancer
samples was performed using LNA-enhanced microarrays, which
contained probes enabling detection of both mature- and pre-
miRNAs based on the miRbase 15.0 database. All data is available
in the GEO dataset (accession number: GSE37405). Initially, the
performance of the hybridization/microarrays was evaluated by
visual inspection and manual flagging of poor quality spots in
addition to Imagene quality analysis. Inspection of spike expres-
sion levels as well as correlation between arrays was checked for
labeling control.
The discovery set was used to examine the ability of miRNA to
sub-group Tamoxifen-treated post-menopausal breast cancer
patients according to outcome, which led to the identification of
10 highly significant miRNAs that distinguished recurrent from
non-recurrent patients (p,6.6e-4, FDR 2.5%) (Fig. 1). The two
test sets were also treated as individual sets to determine whether
miRNAs could separate the N- and R-groups, and whether the
identified miRNAs overlapped. Thirteen miRNAs (p,0.01, FDR
24%, variance .0.1) and 5 miRNAs (p,0.01, FDR 35% and
variance .0.1) were identified for test sets #1 and #2,
respectively, separating patient samples according to outcome
(heat-maps are provided in Figure S1). None of the miRNAs
identified in the test sets overlapped with those from the discovery
set. The Discovery set consisted of matched patients according to
previously detailed prognostic factors, whereas the 2 test sets were
randomly grouped solely according to recurrence status. This lead
to some biological differences wherein the number of tumor-
infiltrated lymph nodes reached significance between the recurrent
vs. non-recurrent groups, with p=0.99, p,0.00001 and p=0.05,
for the discovery, Test set#1 and Test set #2, respectively.
The highly-significant miRNAs identified in the discovery set
were analyzed by survival statistics, yielding a p-value of
pOS=1.2e–05 and prec=0.001 for overall survival (OS) and
probability of recurrence (rec), respectively (Figure 2). Kaplan-
Meier plots for the two test sets, applying the 10 identified
miRNAs did not reach significance, with pOS=0.29 and
prec=0.89 for Test set #1, and pOS=0.3 and prec=0.85 for Test
set #2 (see Figure S2 and S3 for Kaplan-Meier plots).
Furthermore, a supervised analysis according to standard
clinical parameters (as listed in Table 1) was conducted along
with several other clinical parameters such as grade, tumor content
(percent tumor cells of the HE sections) and duration of treatment
with Tamoxifen for the discovery set. A significant correlation was
identified between miR-7 and the tumor grade (Figure 3), but
otherwise no associations were found.
Unsupervised analysis was conducted to delineate miRNAs
potentially related to biological functions. The standard deviation
was used to identify the 100 most variable miRNAs per data set,
unrelated to clinical characteristics. These miRNAs were com-
pared across the 3 sets, leading to the identification of 31 miRNAs.
The biological association of these 31 miRNAs is listed in Table S1
along with experimentally identified targets. Eight of these
miRNAs, miR-141, miR-200a, miR-200b, miR-200c, let-7a, let-
7b, let-7c and miR-205, have been reported to be associated with
cancer stem cell characteristics, such as epithelial-mesenchymal
transition (EMT) and self-renewal.
Discussion
Endocrine resistance of ER+ breast cancer is a major clinical
problem and the focus of intense research. The mechanism of
endocrine resistance is not clearly understood and there is a strong
need for predictive biomarkers that can guide clinicians to identify
patients who will not benefit from adjuvant endocrine treatments,
such as Tamoxifen and AI, and thus would need additional
treatment. MiRNAs have been suggested as promising biomark-
ers, including potential markers of Tamoxifen resistance. Herein
we report the first large-scale global miRNA expression study on
primary tumors from high-risk, ER+, post-menopausal breast
cancer patients who received adjuvant Tamoxifen mono-therapy.
Our study showed that although a highly significant set of 10
miRNAs distinguishing patient samples according to outcome
were identified in the discovery set, the miRNA profile could not
be confirmed in the subsequent two independent test sets. Our
data indicate that there is likely no single, strongly predictive
profile of outcome, and even small imbalances with regard to
prognostic factors between the recurrent/non-recurrent groups,
such as number of tumor-infiltrated lymph nodes at time of
diagnosis, may mask identification of potentially predictive
miRNAs. Further, it may be speculated that endocrine resistance
occurs as a result of several different mechanism, each employing a
set of unique miRNA, complicating the identification of a
common set of miRNAs that is altered in primary tumors of
breast cancer patients who do not have the benefit of adjuvant
Tamoxifen treatment.
This finding is somewhat surprising, since several miRNAs have
been suggested to be associated with Tamoxifen resistance.
However, the majorities of these studies were performed in cell
line models or used very limited numbers of patient samples.
Moreover, several studies identified miRNAs involved in ER
regulation, and thus only indirectly proposed to be involved in
Tamoxifen resistance. One of these, the miR-221/-222 cluster, has
been found to be in a feedback loop with ERa [21] that results in a
decrease in ERa protein, which can lead to resistance towards
Tamoxifen. The reason for not identifying this miRNA cluster in
our study may be related to the fact that most of the patient tumor
samples we analyzed exhibited a very high percentage of ERa
positive cells, with a median of 83% (IHC), across the three sets
(Table 1). Another miRNA, miR-210, was identified in a dataset of
untreated patients consisting of 25 ER-, 40 ER+ and 8 ER-
unknown tumor samples, and therefore likely represents a general
marker for outcome [16], whereas our study focused on resistance
towards Tamoxifen from the onset. Another recent large study
(.100 patient samples) could also not confirm the association of
miR-210 with outcome [22].
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and R-groups were nearly identical according to the strong
prognostic factors that influence the likelihood of developing
recurrence. The two test sets, on the other hand, had more
variable clinical characteristics per group. The most significant
characteristic in test set #1 was the difference in tumor-infiltrated
lymph nodes at time of diagnosis, where the R-group had an
average of 8.6, whereas the N-group had 3.0. For test set #2, there
was a minor difference in the average tumor size and in tumor-
infiltrated lymph nodes, but there was also variation in the
duration of treatment with Tamoxifen. The two test sets were
randomly selected, as opposed to the discovery set, which was
matched, and potential biomarkers, such as miRNAs, would need
the capacity to overcome patient-to-patient variation (random
characteristics) to achieve clinical value. Thus, the miRNA profile
does not seem to provide information with regard to the
probability of recurrence following adjuvant Tamoxifen-treatment
in post-menopausal ER+ breast cancer patients.
The only significant association with a clinical parameter in the
discovery set was miR-7, which was associated with tumor grade
(p=0.02, Figure 3). This miRNA has been found to target,
Figure 1. Heat-map of significantly differentially expressed miRNAs associated with outcome after adjuvant Tamoxifen treatment.
Data is based on the discovery set (p,6.6e-4, FDR 2.5% and variance .0.1). The green symbols above the heat-map indicate samples from patients
with no recurrence, whereas the red symbols indicate samples from patients with recurrence. The heat-map is a standardized intensity plot with the
intensities ranging from 22 (green) to +2 (red).
doi:10.1371/journal.pone.0036170.g001
Figure 2. Kaplan-Meier plots of the 10 miRNAs identified in the
discovery set. The bold line represents the patients with a good
prognosis, whereas the dotted line represents the poor-prognosis
patients. A) Probability of recurrence. B) Probability of overall survival.
doi:10.1371/journal.pone.0036170.g002
Figure 3. Association of miR-7 with tumor grade. Grade 1 vs. 3
and Grade 2 vs. 3: p=0.01, and Grade 1 vs. 2: p=0.02). N=52 patients
(Discovery set).
doi:10.1371/journal.pone.0036170.g003
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on lung cancer found miR-7 to be an oncogenic miRNA, as
EGFR was found to induce miR-7 expression through a Ras/
ERK/Myc pathway, which promoted cell growth and tumor
formation [26], indicating an indirect feedback loop. The
expression of the EGFR has also been negatively associated with
the expression of miR-30c, which was, identified as an indepen-
dent predictor of outcome in advanced breast cancer; high
expression of miR-30c was associated with benefit of Tamoxifen
[27]. Cross-talk between ER and EGFR and its family of growth
factor receptors, especially in its activated phosphorylated form,
has also been shown to be strongly associated with Tamoxifen
resistance [28,29]. We previously conducted a study of mRNA
expression in patient samples from the discovery set and found no
significant association between EGFR mRNA levels and tumor
grade, but a significant association with outcome (p=0.022) [30].
Furthermore, using the same patient material (discovery set), a
significant correlation between the level of pEGFR and outcome
was also observed on a tissue microarray (TMA) [28], but again,
no correlation with grade was observed. It is well-known that
tumor grade is a predictor of poor outcome [31]. The cause of this
lack of consistency between the miRNA and mRNA studies with
regards to associations to outcome may reflect the complexity of
the biological system with multiple miRNAs per target, and that
miRNAs have several targets. Furthermore, the apparent indirect
feedback loop between miR-7 and EGFR is affected by several
other factors, likely masking the known association with grade to
outcome.
To investigate whether there were underlying biological
associations within the tumor samples, we conducted an unsuper-
vised cluster analysis for each of the three patient sample sets. The
miRNAs that exhibited the most variable expression in the
individual set and overlapped across the three sets were selected,
yielded a set of 31 miRNAs (Table S1). Since the discussed
miRNAs were identified by unsupervised analysis, whether they
merely depict the cellular architecture of the tumors or are actually
masked markers for the tumors ability to progress despite adjuvant
treatment with a target-specific drug remains to be determined.
One fourth of the 31 miRNAs were found to be associated with
EMT/MET and stem cell characteristics, and the notion that
cancer stem cells play an important role in endocrine resistance
has recently been discussed [32]. Further studies into this field are
needed. It would also be interesting to conduct in situ hybridization
of the identified miRNAs to visualize the cells they are expressed
in. Also, functional studies would clarify whether targeting
surrounding tissue would induce tumor regression, since it is
well-known that the microenvironment and malignant cells
interact.
Overall, the number of patients in this study provides a strong
foundation for the debate on miRNAs and benefit of Tamoxifen in
post-menopausal ER+ breast cancer patients. This global analysis,
employing the microarray-technique, allows a general estimation
of miRNAs potential and is a common hypothesis-generating
method. This also implies, however, that the significance of single
miRNAs expressed by a subgroup of patients with yet unknown
characteristics may be masked when assessing the groups
collectedly as only general differences are detected.
In conclusion, our data seems to indicate that no single miRNA
profile predictive of outcome for tumors from ER+ breast cancer
patients receiving adjuvant Tamoxifen mono-therapy can be
identified. Our study also highlights the difficulty in identifying
prognostic/predictive markers in a population of patients with
relatively good prognoses. Identification of the few ‘‘poor
prognostic cells’’ may be difficult, as their signal may be
overshadowed by the majority of cells with ‘‘good prognosis’’,
potentially masking the sought-after biomarkers.
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Figure S1 Heat-map of the most significantly differen-
tially expressed miRNAs associated with outcome after
adjuvant Tamoxifen treatment in the A) Test set#1:
p,0.01, FDR 24%, variance .0.1, and B) Test set#2:
p,0.01, FDR 35% and variance .0.1. The green symbols
above the heat-map indicate samples from patients with no
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Figure S2 Kaplan-Meier plots of the 10 miRNAs iden-
tified in the discovery set distinguishing good- and poor-
prognostic patient groups, applied for Test set#1. A)
Probability of recurrence. B) Probability of overall survival.
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Figure S3 Kaplan-Meier plots of the 10 miRNAs iden-
tified in the discovery set distinguishing good- and poor-
prognostic patient groups, applied for Test set#2. A)
Probability of recurrence. B) Probability of overall survival.
(PDF)
Table S1 miRNAs identified across the three datasets of a total
of 152 patient samples, based on the top 100 most variable
miRNAs per set. The table is focused on general characteristics
and/or the relation to breast cancer. Source: www.mir2disease.org
[19].
(PDF)
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